Literature DB >> 35484206

Efficacy and safety of CAR-T cell therapy in minorities.

Astha Thakkar1, Michelly Abreu1, Ira Braunschweig2, Mendel Goldfinger3, Kith Pradhan4, R Alejandro Sica1, Aditi Shastri1, Noah Kornblum1, Nishi Shah1, Ioannis Mantzaris1, Kira Gritsman1, Eric Feldman1, Richard Elkind1, Susan Green-Lorenzen5, Amit Verma1.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2022        PMID: 35484206     DOI: 10.1038/s41409-022-01670-1

Source DB:  PubMed          Journal:  Bone Marrow Transplant        ISSN: 0268-3369            Impact factor:   5.174


× No keyword cloud information.
  11 in total

1.  Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma.

Authors:  Stephen J Schuster; Michael R Bishop; Constantine S Tam; Edmund K Waller; Peter Borchmann; Joseph P McGuirk; Ulrich Jäger; Samantha Jaglowski; Charalambos Andreadis; Jason R Westin; Isabelle Fleury; Veronika Bachanova; S Ronan Foley; P Joy Ho; Stephan Mielke; John M Magenau; Harald Holte; Serafino Pantano; Lida B Pacaud; Rakesh Awasthi; Jufen Chu; Özlem Anak; Gilles Salles; Richard T Maziarz
Journal:  N Engl J Med       Date:  2018-12-01       Impact factor: 91.245

2.  Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study.

Authors:  Jeremy S Abramson; M Lia Palomba; Leo I Gordon; Matthew A Lunning; Michael Wang; Jon Arnason; Amitkumar Mehta; Enkhtsetseg Purev; David G Maloney; Charalambos Andreadis; Alison Sehgal; Scott R Solomon; Nilanjan Ghosh; Tina M Albertson; Jacob Garcia; Ana Kostic; Mary Mallaney; Ken Ogasawara; Kathryn Newhall; Yeonhee Kim; Daniel Li; Tanya Siddiqi
Journal:  Lancet       Date:  2020-09-01       Impact factor: 79.321

3.  Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma.

Authors:  Sattva S Neelapu; Frederick L Locke; Nancy L Bartlett; Lazaros J Lekakis; David B Miklos; Caron A Jacobson; Ira Braunschweig; Olalekan O Oluwole; Tanya Siddiqi; Yi Lin; John M Timmerman; Patrick J Stiff; Jonathan W Friedberg; Ian W Flinn; Andre Goy; Brian T Hill; Mitchell R Smith; Abhinav Deol; Umar Farooq; Peter McSweeney; Javier Munoz; Irit Avivi; Januario E Castro; Jason R Westin; Julio C Chavez; Armin Ghobadi; Krishna V Komanduri; Ronald Levy; Eric D Jacobsen; Thomas E Witzig; Patrick Reagan; Adrian Bot; John Rossi; Lynn Navale; Yizhou Jiang; Jeff Aycock; Meg Elias; David Chang; Jeff Wiezorek; William Y Go
Journal:  N Engl J Med       Date:  2017-12-10       Impact factor: 91.245

4.  Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma.

Authors:  Frederick L Locke; David B Miklos; Caron A Jacobson; Miguel-Angel Perales; Marie-José Kersten; Olalekan O Oluwole; Armin Ghobadi; Aaron P Rapoport; Joseph McGuirk; John M Pagel; Javier Muñoz; Umar Farooq; Tom van Meerten; Patrick M Reagan; Anna Sureda; Ian W Flinn; Peter Vandenberghe; Kevin W Song; Michael Dickinson; Monique C Minnema; Peter A Riedell; Lori A Leslie; Sridhar Chaganti; Yin Yang; Simone Filosto; Jina Shah; Marco Schupp; Christina To; Paul Cheng; Leo I Gordon; Jason R Westin
Journal:  N Engl J Med       Date:  2021-12-11       Impact factor: 91.245

5.  Racial differences in the presentation and outcomes of diffuse large B-cell lymphoma in the United States.

Authors:  Pareen J Shenoy; Neha Malik; Ajay Nooka; Rajni Sinha; Kevin C Ward; Otis W Brawley; Joseph Lipscomb; Christopher R Flowers
Journal:  Cancer       Date:  2010-12-22       Impact factor: 6.860

6.  KTE-X19 CAR T-Cell Therapy in Relapsed or Refractory Mantle-Cell Lymphoma.

Authors:  Michael Wang; Javier Munoz; Andre Goy; Frederick L Locke; Caron A Jacobson; Brian T Hill; John M Timmerman; Houston Holmes; Samantha Jaglowski; Ian W Flinn; Peter A McSweeney; David B Miklos; John M Pagel; Marie-Jose Kersten; Noel Milpied; Henry Fung; Max S Topp; Roch Houot; Amer Beitinjaneh; Weimin Peng; Lianqing Zheng; John M Rossi; Rajul K Jain; Arati V Rao; Patrick M Reagan
Journal:  N Engl J Med       Date:  2020-04-02       Impact factor: 91.245

7.  Racial differences in treatment and survival in older patients with diffuse large B-cell lymphoma (DLBCL).

Authors:  Robert Griffiths; Michelle Gleeson; Kevin Knopf; Mark Danese
Journal:  BMC Cancer       Date:  2010-11-12       Impact factor: 4.430

8.  KTE-X19 for relapsed or refractory adult B-cell acute lymphoblastic leukaemia: phase 2 results of the single-arm, open-label, multicentre ZUMA-3 study.

Authors:  Bijal D Shah; Armin Ghobadi; Olalekan O Oluwole; Aaron C Logan; Nicolas Boissel; Ryan D Cassaday; Thibaut Leguay; Michael R Bishop; Max S Topp; Dimitrios Tzachanis; Kristen M O'Dwyer; Martha L Arellano; Yi Lin; Maria R Baer; Gary J Schiller; Jae H Park; Marion Subklewe; Mehrdad Abedi; Monique C Minnema; William G Wierda; Daniel J DeAngelo; Patrick Stiff; Deepa Jeyakumar; Chaoling Feng; Jinghui Dong; Tong Shen; Francesca Milletti; John M Rossi; Remus Vezan; Behzad Kharabi Masouleh; Roch Houot
Journal:  Lancet       Date:  2021-06-03       Impact factor: 79.321

9.  Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia.

Authors:  Shannon L Maude; Theodore W Laetsch; Jochen Buechner; Susana Rives; Michael Boyer; Henrique Bittencourt; Peter Bader; Michael R Verneris; Heather E Stefanski; Gary D Myers; Muna Qayed; Barbara De Moerloose; Hidefumi Hiramatsu; Krysta Schlis; Kara L Davis; Paul L Martin; Eneida R Nemecek; Gregory A Yanik; Christina Peters; Andre Baruchel; Nicolas Boissel; Francoise Mechinaud; Adriana Balduzzi; Joerg Krueger; Carl H June; Bruce L Levine; Patricia Wood; Tetiana Taran; Mimi Leung; Karen T Mueller; Yiyun Zhang; Kapildeb Sen; David Lebwohl; Michael A Pulsipher; Stephan A Grupp
Journal:  N Engl J Med       Date:  2018-02-01       Impact factor: 91.245

10.  Socioeconomic disparities in mortality after diffuse large B-cell lymphoma in the modern treatment era.

Authors:  Li Tao; James M Foran; Christina A Clarke; Scarlett L Gomez; Theresa H M Keegan
Journal:  Blood       Date:  2014-04-04       Impact factor: 25.476

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.